


SEQENS

OUR SCIENCE FOR YOUR FUTURE

TRUSTED SUPPLIER *of*
Active Pharmaceutical Ingredients



APIs



Foster growth with Seqens

Four custom development and manufacturing organizations – PCAS in France and Finland, Chemie Uetikon in Germany, PCI Synthesis in the United States and Wavelength in Israel & India – have joined forces as Seqens CDMO to offer world-class drug Substance development and manufacturing services to the pharmaceutical industry.

ASSETS & COMPETENCIES

8
cGMP/FDA inspected sites WW

1,000 m³
600 m³ cGMP

Over 35 years of API production experience

3
Pre-GMP sites for RSMs & Building-blocks

200+
DMFs for commercial APIs

In-house back integration of intermediates and starting materials for safe supply

250
scientists, experts and engineers

7
R&D Centers worldwide

Global sales and distribution network


Excellent regulatory compliance track record at all GMP sites

A wide range of technologies

- High Pressure Reaction
- Potent API capabilities: OEL < 100 ng/m³
- Flow chemistry
- Low temperature technology
- API for injectable and ophthalmic FDF
- Micronisation & spray drying
- Enzymatic Chemistry
- Controlled Substances

AN INTERNATIONAL NETWORK

Benefit from a manufacturing network of **8 cGMP plants** located in Europe, United States, Israel and India with a strong **regulatory track record** with international health authorities and the best **workshop & expertise in specialized technologies**



Products Under Development

Product	Therapeutic Area	Stage	Dossier availability
Cantharidin	Molluscum Contagiosum	R&D	
Clascoterone	Acne, Alopecia	R&D	2023
Fluralaner	Anti-Parasitic	Under Evaluation	
Ganaxolone	Epilepsy, Postpartum Depression	R&D	2024
Glycopyronium Bromide Micronized	COPD	R&D	2023
Glycopyrrolate Tosylate	Anticholinergic, Hyperhidrosis	R&D	2023
Lotilaner	Anti-Parasitic	Under Evaluation	
Niraparib Tosylate Monohydrate	Antineoplastic	R&D	2024
Omecamtiv Mecarbil	Chronic Heart Failure	Under Evaluation	
Propofol	Sedation & Anesthesia	R&D	2024
Remimazolam	Sedation, Amnesia, Anesthesia	R&D	2023
R-Ketamine	Antidepressant	R&D	
Ruxolitinib Phosphate	Myelofibrosis, Polycythaemia vera, Graft-versus-host disease	R&D	2024
Sitagliptin HCl Sitagliptin Phosphate	Type II diabetes	R&D	2022
Sparsentan	Antihypertensive	R&D	2024
Tamoxifen Citrate (Ph.Eur,)USP	Oncology	R&D	2023
Tapinarof	Plaque Psoriasis	R&D	2023
Trofinetide	Rett syndrome	Under Evaluation	
Umeclidinium Bromide	COPD	Under Evaluation	
Vamorolone	Duchenne Muscular Dystrophy	Under Evaluation	
Varenicline	Smoking Cessation	R&D	2023



A comprehensive global R&D platform *with unique scientific skills*

- /// In-house Regulatory Affairs team
- /// Solid state development team: Expertise in polymorphism
- /// Customized particle size distribution
- /// In-house IP team for the design of non-infringing patent process

- /// *Lean & Agile*
- /// *Back integrated*
- /// *Powerful R&D*
- /// *Ingenious IP management*
- /// *High level of services*
- /// *Strong supply chain*

NORTH AMERICA

Early phase project



1,000 M² lab-floor
5 Kilo Labs
30 Scientists

- /// Controlled substances (Schedule II-V)

MIDDLE EAST

Small molecules



1,600 M² lab-floor
1 Pilot
42 Scientists

- /// Grams to multi ton GMP scale up
- /// Solid State
- /// Bioavailability enhancement
- /// High potency APIs up to OEB5
- /// Controlled Substances
- /// Spray drying
- /// Micronization
- /// Particle design

EUROPE

Small molecules & polymers



SEQENS'Lab

2,000 M² lab-floor
6 Kilo Labs 3 Pilots
110 Scientists

- /// Crystallization
- /// Solid state & Polymorphism
- /// Flow chemistry
- /// Grams to multi ton GMP scale up
- /// High potency APIs OEL<100 ng/m³

Biocatalysis



protéus
BY SEQENS

1,000 M² Lab floor
8,000 Micro-organisms
library 350 Enzymes available for testing
20 Scientists

- /// Biocatalysis
- /// Tailor made enzymes

ASIA

Advanced Intermediates & Key Starting Materials



750 M² lab-floor
1 Pilot - 1 Kilo lab
38 Scientists

- /// Asymmetric Reductions
- /// Thermal re-arrangements
- /// Acylations
- /// Halogen exchange
- /// Coupling Reactions

API Product list

Product	FDF	EU CEP	EU DMF (ASMF)	US DMF	Bra. DMF	Can. DMF	Jap. DMF	Korea DMF	China DMF	Therapeutic Area
Ammonium Lactate				/						Ichthyosis and Xerosis
Apraclonidine HCl				/						Cardiovascular System
Articain (Carticaine) HCl		/	/	/	/	/				Nervous System
Baclofen		/		/	/	/				Muskulo-skeletal System
Ciclopirox Olamine		/	/			/				Dermatological
Cetirizine Dihydrochloride		/		/						Seasonal and perennial allergic rhinitis
Ciclopirox		/	/	/		/				Dermatological
Cilostazol				/						Intermittent Claudication
Cinacalcet Hydrochloride			/	/		/				Anti-Parathyroid Agents
Cisatracurium Besylate		/		/						Neuromuscular blocking agent
Clomifene Citrate		/		/			/			Genito-urinary system and sex hormones
Clonidine Base			/	/		/				Cardiovascular System
Clonidine HCl		/		/		/		/		
Desipramine HCl				/						Nervous System
Efinaconazole				/						Onychomycosis
Enclomiphene citrate			/	/						Genito-urinary system and sex hormones
Fenofibrate		/		/						Hyperlipidemia; Hypertriglyceridemia
Fexofenadine Hydrochloride				/						Allergy symptoms
Flumazenil		/		/						Benzodiazepines Antidote
Fluticasone Furoate				/						Allergic Rhinitis, COPD
Fluticasone Propionate		/		/						Asthma, COPD
Fulvestrant		/		/						Breast cancer
Glycopyrrolate Bromide		/	/	/		/	/	/*	/	Anticholinergic, Hyperhidrosis
Granisetron Base				/						Chemotherapy-induced nausea and vomiting
Granisetron Hydrochloride	/	/		/						
Halobetasol Propionate				/						Topical anti-inflammatory and antipruritic
Heptaminol Base										Cardiovascular System
Heptaminol HCl		/	/							
Imiquimod				/						Actinic Keratosis/Superficial Basal Cell Carcinoma
Ketamine HCl		/		/		/	/	/		Nervous System
S-Ketamine HCl		/		/		/		/		
Mepenzolate Bromide							/			Alimentary tract and metabolism
Mepivacaine HCl		/		/		/				Nervous System
Methimazole (Thiamazol)		/		/		/	/	/	/	Hyperthyroidism
Mequitazine			/				/	/		Allergy Symptoms
Midazolam		/		/						Sedation; Amnesia; Anesthesia
Mifepristone		/					/			Progesterone receptor antagonist
Modafinil		/		/						Narcolepsy / Obstructive Sleep Apnea
Mometasone Furoate Anhydrous				/						Asthma

Product	FDF	EU CEP	EU DMF (ASMF)	US DMF	Bra. DMF	Can. DMF	Jap. DMF	Korea DMF	China DMF	Therapeutic Area
Mometasone Furoate Monohydrate		//*		//						Allergic Rhinitis
Moxonidine	//	//								Hypertension
Olopatadine HCl			//	//	//	//			//	Respiratory System
Oxeladin Citrate			//							Respiratory System
Oxybutynin Base			//	//		//	//	//		Overactive Bladder
Oxybutynin HCl		//	//	//	//	//	//	//		
Palonosetron Hydrochloride			//	//						Chemotherapy Induced / Post-operative Nausea
Permethrin		//		//						Treatment for scabies
Pholcodine		//							//	Respiratory System
Pindolol		//	//	//		//				Cardiovascular System
Piperidolate HCl					//		//			Alimentary tract and metabolism
Podophyllotoxin				//						Dermatological
Pralidoxime Chloride				//						Treatment of poisoning by organophosphorus chemicals
Pramipexole Dihydrochloride				//						Parkinson's disease
Praziquantel		//		//		//				Antiparasitic
Promazine HCl		//	//							Nervous System
Pyridostigmine Bromide				//						Nervous System
Rocuronium Bromide				//						Neuromuscular blocking agent
Rotigotine				//						Parkinson's disease
Sodium Phenyl Butyrate			//	//		//	//			Alimentary tract and metabolism
Sugammadex				//						Vecuronium / Rocuronium Antidote
Tamoxifene Citrate						//				Oncology
Tazarotene			//	//		//				Dermatological
Temozolomide	//		//	//		//				Glioblastoma multiforme (GBM)
Tetrahydrozoline		//	//					//*		Ophthalmic
Tiotropium Bromide Monohydrate		//		//						COPD
Timolol Hemihydrate				//						Ophthalmic
Timolol Maleate		//	//	//						Ophthalmic
Tramadol Hydrochloride		//		//						Pain
Trimeprazine (Alimemazine) Tartrate		//	//	//			//			Respiratory System
Troxerutine		//	//							Cardiovascular System

* In progress.

DMFs registered under the names of the following SEQENS legal entities: PCAS, Chemie Uetikon, Wavelength and PCI Synthesis



About Seqens

SEQENS is a worldwide leader in the development and production of active ingredients, pharmaceutical intermediates and specialty ingredients leveraging on 24 manufacturing sites, 10 R&D centers and 3,400 employees in 10 countries.

As an integrated player across the value chain - from raw materials to active ingredients and from research and development to industrialization - SEQENS offers a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients, develops and industrializes the most demanding molecules, and relies on its ability to innovate, develop and implement the best available technologies.

Driven by a culture of excellence and a strong entrepreneurial spirit, but also strong values such as unity, tenacity, agility and reactivity, our employees are committed to providing more than 1000 customers in the world with the highest level of service and quality while acting ethically in accordance with our strong Environmental, Social and Governance program.

In the pharmaceutical industry, Seqens supports its customers in developing, scaling up and manufacturing drug substances from the pre-clinical phase to the commercial phase. Seqens also offers a large portfolio of APIs and proprietary products.



3,400
people



>300
scientists, experts
and engineers



10
R&D centers



1,000
clients in more
than 80 countries



24
manufacturing
sites

DISCOVER SEQENS PHARMA SOLUTIONS PRODUCTS & SERVICES OFFER

Custom
manufacturing

Intermediates

Biocatalysis
services

Early stage
manufacturing

Drug delivery &
Medical material

Contact :
PAPI@seqens.com

SEQENS

21 CHEMIN DE LA SAUVEGARDE
CS 33167
69130 ECULLY CEDEX
TEL. +33 (0) 4 26 99 18 00
FAX. +33 (0) 4 26 99 18 38

www.seqens.com

